The industry speaks: what is the future of CAR-T cell therapy?

CAR-T cell therapy enters its next decade with hard-won momentum and unresolved challenges in equal measure. The science is advancing. The system has not yet caught up. Closing that gap, on access, on reimbursement, on regulatory engagement, will define whether the promise of CAR-T is realized for the many or remains out of reach for the patients who need it most.

This pressing challenge brought together 38 leading experts from industry and academia  for an invitation-only event exploring the field's most urgent priorities — captured across six live polls over two days .

Read the full infographic below

Please enter your email to access content Read now